Pharmaceutical maker Moderna announced Tuesday that the U.S. Food and Drug Administration (FDA) issued a refusal-to-file letter regarding its application for an mRNA-based influenza vaccine, mRNA-1010. The FDA's Center for Biologics Evaluation and Research cited concerns about the trial design.
FDA Rejects Moderna's mRNA Flu Vaccine Over Trial Design